For research use only. Not for therapeutic Use.
Fosfomycin Tromethamine（Cat No.:R043519）is an antibiotic used in the treatment of urinary tract infections (UTIs). It works by inhibiting bacterial cell wall synthesis, preventing the growth of bacteria. This compound is particularly effective against Gram-positive and Gram-negative organisms, including E. coli, the most common cause of UTIs. Fosfomycin is often administered as a single-dose therapy, providing a convenient option for outpatient management of uncomplicated UTIs. Its broad-spectrum activity, low resistance potential, and oral bioavailability make it a valuable option in both hospital and community settings for UTI treatment.
| Catalog Number | R043519 |
| CAS Number | 78964-85-9 |
| Synonyms | P-[(2R,3S)-3-Methyl-2-oxiranyl]phosphonic Acid compd. with 2-Amino-2-(hydroxymethyl)-1,3-propanediol;?(3-Methyloxiranyl)phosphonic Acid compd. with 2-Amino-2-(hydroxymethyl)-1,3-propanediol; [(2R,3S)-3-Methyloxiranyl]phosphonic Acid compd. with 2-Am |
| Molecular Formula | C₇H₁₈NO₇P |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | 2-amino-2-(hydroxymethyl)propane-1,3-diol;[(2R,3S)-3-methyloxiran-2-yl]phosphonic acid |
| InChI | InChI=1S/C4H11NO3.C3H7O4P/c5-4(1-6,2-7)3-8;1-2-3(7-2)8(4,5)6/h6-8H,1-3,5H2;2-3H,1H3,(H2,4,5,6)/t;2-,3+/m.0/s1 |
| InChIKey | QZJIMDIBFFHQDW-LMLSDSMGSA-N |
| SMILES | C[C@H]1[C@H](O1)P(=O)(O)O.C(C(CO)(CO)N)O |
| Reference | </br>1:Fosfomycin tromethamine for the Treatment of Cystitis in Abdominal Solid Organ Transplant Recipients With Renal Dysfunction. Kerstenetzky L, Jorgenson MR, Descourouez JL, Leverson G, Rose WE, Redfield RR, Smith JA.Ann Pharmacother. 2017 May 1:1060028017710252. doi: 10.1177/1060028017710252. [Epub ahead of print] PMID: 28511545 </br>2:Potential Use of Fosfomycin-Tromethamine for Treatment of Recurrent Campylobacter Species Enteritis. Aguilar-Company J, Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Larrosa MN, Rodríguez-Garrido V, Sihuay-Diburga D, Almirante B.Antimicrob Agents Chemother. 2016 Jun 20;60(7):4398-400. doi: 10.1128/AAC.00447-16. Print 2016 Jul. PMID: 27161640 Free PMC Article</br>3:Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis. Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Fernández-Hidalgo N, Andreu A, Larrosa N, Almirante B.Antimicrob Agents Chemother. 2015 Dec 14;60(3):1854-8. doi: 10.1128/AAC.02611-15. PMID: 26666924 Free PMC Article</br>4:Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study. Khawaja AR, Khan FB, Dar TI, Bhat AH, Wani MS, Wazir BS.Cent European J Urol. 2015;68(3):371-5. doi: 10.5173/ceju.2015.590. Epub 2015 Oct 15. PMID: 26568884 Free PMC Article</br>5:In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria. Khan IU, Mirza IA, Ikram A, Ali S, Hussain A, Ghafoor T.J Coll Physicians Surg Pak. 2014 Dec;24(12):914-7. doi: 12.2014/JCPSP.914917. PMID: 25523727 </br>6:Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. Qiao LD, Zheng B, Chen S, Yang Y, Zhang K, Guo HF, Yang B, Niu YJ, Wang Y, Shi BK, Yang WM, Zhao XK, Gao XF, Chen M.BMJ Open. 2013 Dec 4;3(12):e004157. doi: 10.1136/bmjopen-2013-004157. PMID: 24309172 Free PMC Article</br>7:Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Demir T, Buyukguclu T.Int J Infect Dis. 2013 Nov;17(11):e966-70. doi: 10.1016/j.ijid.2013.04.005. Epub 2013 Jun 3. PMID: 23742831 Free Article</br>8:Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? Knottnerus BJ, Nys S, Ter Riet G, Donker G, Geerlings SE, Stobberingh E.J Antimicrob Chemother. 2008 Aug;62(2):356-9. doi: 10.1093/jac/dkn177. Epub 2008 Apr 19. PMID: 18424789 </br>9:Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli. Tullio V, Cuffini AM, Banche G, Mandras N, Allizond V, Roana J, Giacchino F, Bonello F, Ungheri D, Carlone NA.Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):153-60. PMID: 18336741 </br>10:In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates. Cilli F, Pullukcu H, Aydemir S, Sipahi OR, Tasbakan M, Turhan A, Ulusoy S.Int J Antimicrob Agents. 2008 Mar;31(3):297-8. doi: 10.1016/j.ijantimicag.2007.11.003. Epub 2008 Jan 3. No abstract available. PMID: 18180144 |
